ChinaBio Today -- The international profile of the China CRO industry, which is already well established, was raised even further last week when HD Biosciences Co., Ltd., the Shanghai-based biotech CRO, was given the “2008 Top Research Service Partner” award by big pharma Pfizer (NYSE: PFE) (see story). Specifically, the award recognized the quality, productivity, and value that HD Biosciences delivered in its collaboration with Pfizer during the past year. Last week, to mark the giving of the award, we profiled the company—its history, its offerings—including an exclusive interview with CEO and Founder Dr. Xuehai Tan. HD Biosciences is focused entirely on biology service in drug development, a fairly unusual niche that differentiates the company from most China CROs. “We stay focused on the things we do the best,” said Dr Tan. “We will not try to do everything. But, we are the leaders in what we do.”
